{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:47:34Z","timestamp":1786985254672,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"Horizon 2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["860715"],"award-info":[{"award-number":["860715"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["18OI17"],"award-info":[{"award-number":["18OI17"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118880","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:29:09Z","timestamp":1764952149000},"page":"118880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["In vitro assessment of pirfenidone anti-fibrotic properties in a humanized 3D bioprinted kidney tubulointerstitium model"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2173-0371","authenticated-orcid":false,"given":"Gabriele","family":"Addario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bortolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Moroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5935-6245","authenticated-orcid":false,"given":"Carlos","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.biopha.2025.118880_bib1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1369\/0022155419849388","article-title":"Extracellular matrix in kidney fibrosis: more than just a scaffold","volume":"67","author":"Bulow","year":"2019","journal-title":"J. Histochem Cytochem"},{"issue":"13","key":"10.1016\/j.biopha.2025.118880_bib2","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.biopha.2025.118880_bib3","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jamainternmed.2021.4813","article-title":"Accounting for age in the definition of chronic kidney disease","volume":"181","author":"Liu","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.biopha.2025.118880_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.mam.2018.06.002","article-title":"Cellular and molecular mechanisms of kidney fibrosis","volume":"65","author":"Djudjaj","year":"2019","journal-title":"Mol. Asp. Med"},{"key":"10.1016\/j.biopha.2025.118880_bib5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fphar.2017.00520","article-title":"Progression of tubulointerstitial fibrosis and the chronic kidney disease phenotype - role of risk factors and epigenetics","volume":"8","author":"Hewitson","year":"2017","journal-title":"Front Pharm."},{"issue":"10302","key":"10.1016\/j.biopha.2025.118880_bib6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.biopha.2025.118880_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.ackd.2016.11.002","article-title":"Treatment of renal fibrosis-turning challenges into opportunities","volume":"24","author":"Klinkhammer","year":"2017","journal-title":"Adv. Chronic Kidney Dis."},{"key":"10.1016\/j.biopha.2025.118880_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174503","article-title":"Pirfenidone is a renal protective drug: mechanisms, signalling pathways, and preclinical evidence","volume":"911","author":"Bai","year":"2021","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118880_bib9","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2021.30","article-title":"Pirfenidone for idiopathic pulmonary fibrosis and beyond","volume":"8","author":"Aimo","year":"2022","journal-title":"Card. Fail Rev."},{"issue":"Pt 7","key":"10.1016\/j.biopha.2025.118880_bib10","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1107\/S2056989019006418","article-title":"Crystal structure of pirfenidone (5-methyl-1-phenyl-1H-pyridin-2-one): an active pharmaceutical ingredient (API)","volume":"75","author":"Barbero","year":"2019","journal-title":"Acta Crystallogr E Crystallogr Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118880_bib11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","article-title":"Targeting fibrosis, mechanisms and cilinical trials","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2025.118880_bib12","article-title":"The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1","volume":"7","author":"Yue","year":"2021","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.biopha.2025.118880_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030775","article-title":"Pirfenidone inhibits cell proliferation and collagen I production of primary human intestinal fibroblasts","volume":"9","author":"Cui","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biopha.2025.118880_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s10020-020-00173-3","article-title":"Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt\/GSK-3beta\/beta-catenin and TGF-beta1\/Smad2\/3 signaling pathways","volume":"26","author":"Lv","year":"2020","journal-title":"Mol. Med."},{"issue":"8","key":"10.1016\/j.biopha.2025.118880_bib15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/nep.12831","article-title":"Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis","volume":"22","author":"Li","year":"2017","journal-title":"Nephrol. (Carlton)"},{"issue":"1-3","key":"10.1016\/j.biopha.2025.118880_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejphar.2009.12.011","article-title":"Renoprotective properties of pirfenidone in subtotally nephrectomized rats","volume":"629","author":"Takakuta","year":"2010","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118880_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.854314","article-title":"Pirfenidone has anti-fibrotic effects in a tissue-engineered model of human cardiac fibrosis","volume":"9","author":"Bracco Gartner","year":"2022","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.biopha.2025.118880_bib18","article-title":"3D pulmonary fibrosis model for anti-fibrotic drug discovery by inkjet-bioprinting","volume":"18","author":"Dayoon Kang","year":"2023","journal-title":"Biomed. Mater."},{"issue":"21","key":"10.1016\/j.biopha.2025.118880_bib19","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1039\/D3LC00393K","article-title":"A biomimetic renal fibrosis progression model on-chip evaluates anti-fibrotic effects longitudinally in a dynamic fibrogenic niche","volume":"23","author":"Wu","year":"2023","journal-title":"Lab Chip"},{"issue":"1","key":"10.1016\/j.biopha.2025.118880_bib20","doi-asserted-by":"crossref","first-page":"14490","DOI":"10.1038\/s41598-017-12683-y","article-title":"Monitoring and manipulating cellular crosstalk during kidney fibrosis inside a 3D in vitro co-culture","volume":"7","author":"Nugraha","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118880_bib21","article-title":"Pirfenidone effectively reverses experimental liver fibrosis","volume":"37","author":"Leonel","year":"2002","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118880_bib22","article-title":"Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5\/6 nephrectomized rats","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"issue":"9779","key":"10.1016\/j.biopha.2025.118880_bib23","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118880_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1191\/1352458505ms1134oa","article-title":"A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis","volume":"11","author":"Walker","year":"2005","journal-title":"Mult. Scler."},{"key":"10.1016\/j.biopha.2025.118880_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-230X-14-131","article-title":"Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C","volume":"14","author":"Flores-Contreras","year":"2014","journal-title":"BMC Gastroenterol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118880_bib26","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1681\/ASN.2010101049","article-title":"Pirfenidone for diabetic nephropathy","volume":"22","author":"Sharma","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2025.118880_bib27","first-page":"15","article-title":"Human disease models in drug development","volume":"1","author":"Loewa","year":"2023","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.biopha.2025.118880_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.addr.2013.12.002","article-title":"Tissue-engineered kidney disease models","volume":"69-70","author":"Desrochers","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2025.118880_bib29","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1042\/EBC20200158","article-title":"Bioprinting of kidney in vitro models: cells, biomaterials, and manufacturing techniques","volume":"65","author":"Fransen","year":"2021","journal-title":"Essays Biochem"},{"issue":"5","key":"10.1016\/j.biopha.2025.118880_bib30","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ajpath.2022.01.009","article-title":"Human kidney organoids and tubuloids as models of complex kidney disease","volume":"192","author":"Nunez-Nescolarde","year":"2022","journal-title":"Am. J. Pathol."},{"issue":"29","key":"10.1016\/j.biopha.2025.118880_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400807","article-title":"3D humanized bioprinted tubulointerstitium model to emulate renal fibrosis in vitro","volume":"13","author":"Addario","year":"2024","journal-title":"Adv. Health Mater."},{"issue":"4","key":"10.1016\/j.biopha.2025.118880_bib32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000499506","article-title":"Spontaneous extracellular matrix accumulation in a human in vitro model of renal fibrosis is mediated by \u03b1V integrins","volume":"142","author":"Bon","year":"2019","journal-title":"Nephron"},{"issue":"10","key":"10.1016\/j.biopha.2025.118880_bib33","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1242\/bio.025866","article-title":"An immunofluorescence assay for extracellular matrix components highlights the role of epithelial cells in producing a stable, fibrillar extracellular matrix","volume":"6","author":"Qureshi","year":"2017","journal-title":"Biol. Open"},{"issue":"7","key":"10.1016\/j.biopha.2025.118880_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21070862","article-title":"Pingyangmycin and bleomycin share the same cytotoxicity pathway","volume":"21","author":"He","year":"2016","journal-title":"Molecules"},{"issue":"18","key":"10.1016\/j.biopha.2025.118880_bib35","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1016\/j.bmc.2016.07.020","article-title":"Synthesis and anticancer potential of novel xanthone derivatives with 3,6-substituted chains","volume":"24","author":"Liu","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118880_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.mex.2023.102416","article-title":"Histochemical and biochemical analysis of collagen content in formalin-fixed, paraffin embedded colonic samples","volume":"11","author":"Baidoo","year":"2023","journal-title":"MethodsX"},{"issue":"4","key":"10.1016\/j.biopha.2025.118880_bib37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2144\/000112401","article-title":"Isolation and solubilization of proteins after TRIzol\u00ae extraction of RNA and DNA from patient material following prolonged storage","volume":"42","author":"Hummon","year":"2007","journal-title":"BioTechniques"},{"issue":"7","key":"10.1016\/j.biopha.2025.118880_bib38","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.biopha.2025.118880_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.kint.2023.03.007","article-title":"International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology","volume":"104","author":"Nangaku","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.biopha.2025.118880_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101191","article-title":"Mechanisms of organ fibrosis: emerging concepts and implications for novel treatment strategies","volume":"92","author":"Lurje","year":"2023","journal-title":"Mol. Asp. Med"},{"issue":"12","key":"10.1016\/j.biopha.2025.118880_bib41","article-title":"TGF-beta inhibitors for therapeutic management of kidney fibrosis","volume":"15","author":"Park","year":"2022","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.biopha.2025.118880_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2022.107238","article-title":"Non-uniformity in in vitro drug-induced cytotoxicity as evidenced by differences in IC(50) values - implications and way forward","volume":"119","author":"Arokia Femina","year":"2023","journal-title":"J. Pharm. Toxicol. Methods"},{"issue":"1","key":"10.1016\/j.biopha.2025.118880_bib43","doi-asserted-by":"crossref","first-page":"9963","DOI":"10.1038\/s41598-017-10298-x","article-title":"Quantitative and organisational changes in mature extracellular matrix revealed through high-content imaging of total protein fluorescently stained in situ","volume":"7","author":"Holdsworth","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2025.118880_bib44","doi-asserted-by":"crossref","first-page":"F561","DOI":"10.1152\/ajprenal.00036.2017","article-title":"Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis","volume":"313","author":"Ding","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118880_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12050459","article-title":"Predictive value of precision-cut kidney slices as an Ex vivo screening platform for therapeutics in human renal fibrosis","volume":"12","author":"Bigaeva","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.biopha.2025.118880_bib46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1165\/rcmb.2016-0217OC","article-title":"A novel antifibrotic mechanism of nintedanib and pirfenidone. Inhibition of collagen fibril assembly","volume":"57","author":"Knuppel","year":"2017","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118880_bib47","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/kidneydial2040055","article-title":"Cell-matrix interactions in renal fibrosis","volume":"2","author":"Kim","year":"2022","journal-title":"Kidney Dial."},{"issue":"2","key":"10.1016\/j.biopha.2025.118880_bib48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ki.5000054","article-title":"Renal fibrosis: new insights into the pathogenesis and therapeutics","volume":"69","author":"Liu","year":"2006","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.biopha.2025.118880_bib49","doi-asserted-by":"crossref","first-page":"2403230","DOI":"10.1002\/adhm.202403230","article-title":"Kidney fibrosis in vitro and in vivo models: path toward physiologically relevant humanized models","volume":"14","author":"Addario","year":"2025","journal-title":"Adv. Healthc. Mater."},{"issue":"3","key":"10.1016\/j.biopha.2025.118880_bib50","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2613.2011.00764.x","article-title":"Fibroblasts and myofibroblasts in renal fibrosis","volume":"92","author":"Meran","year":"2011","journal-title":"Int J. Exp. Pathol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118880_bib51","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1681\/ASN.2012111112","article-title":"NADPH oxidases, reactive oxygen species, and the kidney: friend and foe","volume":"24","author":"Sedeek","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2025.118880_bib52","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.redox.2015.09.009","article-title":"Reciprocal regulation of TGF-beta and reactive oxygen species: a perverse cycle for fibrosis","volume":"6","author":"Liu","year":"2015","journal-title":"Redox Biol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118880_bib53","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00441-016-2445-3","article-title":"Reactive oxygen species and fibrosis: further evidence of a significant liaison","volume":"365","author":"Richter","year":"2016","journal-title":"Cell Tissue Res."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:49:37Z","timestamp":1777013377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225010741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":53,"alternative-id":["S0753332225010741"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118880","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro assessment of pirfenidone anti-fibrotic properties in a humanized 3D bioprinted kidney tubulointerstitium model","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118880"}}